ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
Company profile
Ticker
PTCT
Exchange
Website
CEO
Stuart Peltz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PTC THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
PTC Therapeutics International Limited • PTC Therapeutics GT, Inc. ...
IRS number
43416587
PTCT stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
28 Sep 23
8-K
Other Events
22 Sep 23
8-K
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
15 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Results of Operations and Financial Condition
3 Aug 23
8-K
Regulation FD Disclosure
19 Jul 23
8-K
Departure of Directors or Certain Officers
17 Jul 23
8-K
Regulation FD Disclosure
21 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 23
8-K
PTC Therapeutics Announces Strategic Pipeline Prioritization
23 May 23
Transcripts
PTCT
Earnings call transcript
2023 Q2
3 Aug 23
PTCT
Earnings call transcript
2022 Q4
21 Feb 23
PTCT
Earnings call transcript
2022 Q3
27 Oct 22
PTCT
Earnings call transcript
2022 Q2
7 Aug 22
PTCT
Earnings call transcript
2022 Q1
4 May 22
PTCT
Earnings call transcript
2021 Q4
23 Feb 22
PTCT
Earnings call transcript
2021 Q3
29 Oct 21
PTCT
Earnings call transcript
2021 Q2
30 Jul 21
PTCT
Earnings call transcript
2021 Q1
6 May 21
PTCT
Earnings call transcript
2020 Q4
26 Feb 21
Latest ownership filings
4
Alethia Young
8 Sep 23
144
Notice of proposed sale of securities
6 Sep 23
4
Pierre Gravier
17 Jul 23
3
Pierre Gravier
17 Jul 23
SC 13D/A
ClearPoint Neuro, Inc.
15 Jun 23
3
Lee Scott Golden
13 Jun 23
4
MICHAEL SCHMERTZLER
9 Jun 23
4
William F. Jr. Bell
7 Jun 23
3
William F. Jr. Bell
7 Jun 23
144
Notice of proposed sale of securities
7 Jun 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 224.50 mm | 224.50 mm | 224.50 mm | 224.50 mm | 224.50 mm | 224.50 mm |
| Cash burn (monthly) | 3.03 mm | (no burn) | 79.16 mm | 58.33 mm | 4.71 mm | 20.63 mm |
| Cash used (since last report) | 9.15 mm | n/a | 238.89 mm | 176.04 mm | 14.20 mm | 62.27 mm |
| Cash remaining | 215.34 mm | n/a | -14.39 mm | 48.45 mm | 210.29 mm | 162.22 mm |
| Runway (months of cash) | 71.0 | n/a | -0.2 | 0.8 | 44.7 | 7.9 |
Institutional ownership, Q2 2023
| 13F holders | Current |
|---|---|
| Total holders | 524 |
| Opened positions | 69 |
| Closed positions | 58 |
| Increased positions | 178 |
| Reduced positions | 184 |
| 13F shares | Current |
|---|---|
| Total value | 14.27 tn |
| Total shares | 108.04 mm |
| Total puts | 219.40 k |
| Total calls | 227.60 k |
| Total put/call ratio | 1.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 13.01 mm | $1.85 tn |
| BLK Blackrock | 10.15 mm | $1.44 tn |
| ROK Rockwell Automation | 6.07 mm | $855.82 mm |
| T. Rowe Price Investment Management | 4.77 mm | $682.51 bn |
| Pictet Asset Management | 4.76 mm | $677.73 bn |
| STT State Street | 4.32 mm | $614.64 bn |
| Alliancebernstein | 3.77 mm | $537.14 bn |
| Lone Pine Capital | 3.17 mm | $450.74 bn |
| Select Equity | 3.00 mm | $427.55 bn |
| Geode Capital Management | 2.42 mm | $343.33 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 Sep 23 | Alethia Young | Common Stock | Sell | Dispose S | No | No | 39.7926 | 4,666 | 185.67 k | 9,067 |
| 6 Sep 23 | Alethia Young | Common Stock | Option exercise | Acquire M | No | No | 27.85 | 4,666 | 129.95 k | 13,733 |
| 6 Sep 23 | Alethia Young | Common Stock | Sell | Dispose S | No | No | 39.9 | 7,000 | 279.30 k | 9,067 |
| 6 Sep 23 | Alethia Young | Common Stock | Option exercise | Acquire M | No | No | 27.85 | 7,000 | 194.95 k | 16,067 |
| 6 Sep 23 | Alethia Young | Stock Option Common Stock | Option exercise | Dispose M | No | No | 27.85 | 4,666 | 129.95 k | 7,334 |
| 6 Sep 23 | Alethia Young | Stock Option Common Stock | Option exercise | Dispose M | No | No | 27.85 | 7,000 | 194.95 k | 0 |
| 13 Jul 23 | Pierre Gravier | Common Stock | Grant | Acquire A | No | No | 0 | 26,000 | 0.00 | 26,000 |
| 13 Jul 23 | Pierre Gravier | Stock Option Common Stock | Grant | Acquire A | No | No | 39.82 | 65,000 | 2.59 mm | 65,000 |
| 7 Jun 23 | Schmertzler Michael | Common Stock | Sell | Dispose S | No | Yes | 44.86 | 1,000 | 44.86 k | 116,766 |
News
Expert Ratings for PTC Therapeutics
19 Sep 23
Truist Securities Reiterates Buy on PTC Therapeutics, Maintains $45 Price Target
19 Sep 23
Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday
19 Sep 23
B of A Securities Maintains Underperform on PTC Therapeutics, Lowers Price Target to $23
19 Sep 23
Truist Securities Maintains Buy on PTC Therapeutics, Lowers Price Target to $45
18 Sep 23
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
29 Sep 23
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
28 Sep 23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
21 Sep 23
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
15 Sep 23
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
12 Sep 23